Arcturus Therapeutics Logo
US03969T1097
A2PMAS
ARCT

Arcturus Therapeutics

Previsão

O preço-alvo médio dos analistas é € 27,80 (+309,43%). A mediana é € 27,80 (+309,43%).

Comprar
  12
Manter
  5
Vender
  4

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon

    Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Mais em de.investing.com


  • Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts

    At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Mais em de.investing.com


  • Arcturus Therapeutics jumps after management signal and conference announcements

    Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Mais em de.investing.com


  • Arcturus highlights strong liquidity and upcoming clinical catalysts

    Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Mais em de.investing.com


  • Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop

    Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Mais em de.investing.com

Em 2012, Arcturus Therapeutics já distribuiu € 2,66 em dividendos. A última distribuição ocorreu em dezembro de 2012.

Dados financeiros

No último trimestre, Arcturus Therapeutics registou receitas de € 16,15 mi e um ganho líquido de -€ 6,55 mi

(EUR) setembro de 2026
YoY
Receitas 16,15 mi 10,53%
Ganho bruto 16,15 mi 37,28%
Ganho líquido -6,55 mi 42,88%
EBITDA -6,55 mi 39,45%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 211,19 mi
Número de ações
28,82 mi
Máximo/mínimo de 52 semanas
€ 16,37 - € 5,01
Dividendos Não
Beta
2,61
PER (PE Ratio)
-2,59
PEG (PEG Ratio)
0,10
P/VC (PB Ratio)
1,36
P/V (PS Ratio)
9,29

Perfil da empresa

A Arcturus Therapeutics Holdings Inc., uma empresa de medicamentos de ARN, centra-se no desenvolvimento de vacinas para doenças infeciosas, e de doenças raras do fígado e do sistema respiratório nos Estados Unidos. Os programas de desenvolvimento da empresa incluem o programa de desenvolvimento LUNAR-OTC para a deficiência de ornitina transcarbamilase (OTC); e o programa LUNAR-CF para a doença pulmonar da fibrose quística causada por mutações no gene do regulador de condutância transmembranar da fibrose quística (CFTR), bem como programas de vacinas que incluem a LUNAR-COV19 e a LUNAR-FLU. A empresa tem parcerias de colaboração com a Vinbiocare Biotechnology Joint Stock Company para a fabricação de vacinas contra a COVID-19; a Janssen Pharmaceuticals, Inc. para desenvolver candidatos terapêuticos baseados em ácidos nucleicos para o tratamento do vírus da hepatite B; a Ultragenyx Pharmaceutical, Inc. para desenvolver candidatos terapêuticos de mRNA para alvos de doenças raras; a CureVac AG para desenvolver candidatos terapêuticos e de vacinas de mRNA para várias indicações; o Conselho de Desenvolvimento Económico de Singapura e a Duke-NUS Medical School para desenvolver a vacina LUNAR-COV19; e a Millennium Pharmaceuticals, Inc. para descobrir medicamentos de siRNA para o tratamento da esteato-hepatite não alcoólica. A empresa foi fundada em 2013 e tem sede em San Diego, Califórnia.

Nome
Arcturus Therapeutics
CEO
Joseph E. Payne
Sede San Diego, ca
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
22/05/2013
Colaboradores 109

Símbolos de ticker

Bolsa Símbolo
NASDAQ
ARCT
🍪

Parqet  utiliza cookies. Saber mais